Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015
Source: Spiolto Respimat shown to be superior first line therapy over...